Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

Mehmet Oz, M.D., says he will divest from insurance, provider and drugmakers if he earns confirmation from the Senate to run ...

Dr. Mehmet Oz has pledged to eliminate his conflicts of interest before he would helm the Centers for Medicare and Medicaid ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...